

## Byetta<sup>®</sup> (exenatide) – First-time generic

- On April 7, 2025, [Amneal launched](#) an [AP-rated](#) generic version of AstraZeneca's [Byetta \(exenatide\)](#) 10 mcg per dose (2.4 mL) subcutaneous (SC) pen-injector.
  - Amneal also received FDA approval of an [AP-rated](#) exenatide 5 mcg per dose (1.2 mL) SC pen-injector. Launch is pending for this strength.
  - [AstraZeneca announced](#) the discontinuation of Byetta prefilled pens in October 2024.
- Byetta is approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.